HK1257466A2 - 皮膚病的藥物製劑 - Google Patents
皮膚病的藥物製劑Info
- Publication number
- HK1257466A2 HK1257466A2 HK18108035A HK18108035A HK1257466A2 HK 1257466 A2 HK1257466 A2 HK 1257466A2 HK 18108035 A HK18108035 A HK 18108035A HK 18108035 A HK18108035 A HK 18108035A HK 1257466 A2 HK1257466 A2 HK 1257466A2
- Authority
- HK
- Hong Kong
- Prior art keywords
- drug formulation
- dermal diseases
- dermal
- diseases
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK18108035A HK1257466A2 (zh) | 2018-06-22 | 2018-06-22 | 皮膚病的藥物製劑 |
CN201980041247.9A CN112292152A (zh) | 2018-06-22 | 2019-06-21 | 皮肤病用药物制剂 |
US17/254,685 US20210268123A1 (en) | 2018-06-22 | 2019-06-21 | Drug formulation for dermal diseases |
EP19822662.3A EP3810202A4 (en) | 2018-06-22 | 2019-06-21 | DRUG FORMULATION FOR DERMAL DISEASES |
PCT/CN2019/092173 WO2019242706A1 (en) | 2018-06-22 | 2019-06-21 | Drug formulation for dermal diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK18108035A HK1257466A2 (zh) | 2018-06-22 | 2018-06-22 | 皮膚病的藥物製劑 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257466A2 true HK1257466A2 (zh) | 2019-10-18 |
Family
ID=68465536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18108035A HK1257466A2 (zh) | 2018-06-22 | 2018-06-22 | 皮膚病的藥物製劑 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210268123A1 (zh) |
EP (1) | EP3810202A4 (zh) |
CN (1) | CN112292152A (zh) |
HK (1) | HK1257466A2 (zh) |
WO (1) | WO2019242706A1 (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10799593B2 (en) * | 2008-06-09 | 2020-10-13 | Northwestern University | Nanodiamond particle complexes |
CN101288643B (zh) * | 2008-06-17 | 2012-11-14 | 杨喜鸿 | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 |
EP3265961A1 (en) * | 2015-03-02 | 2018-01-10 | Taaneh, Inc. | Authenticated systems employing fluorescent diamond particles |
CN105949733B (zh) * | 2016-05-24 | 2018-02-13 | 河北工业大学 | 一种温敏型嵌段共聚物修饰纳米金刚石的方法 |
CN107929242B (zh) * | 2017-11-26 | 2020-01-07 | 郑州大学 | 基于纳米金刚石的药物载体、药物复合体及其制备方法和应用 |
-
2018
- 2018-06-22 HK HK18108035A patent/HK1257466A2/zh unknown
-
2019
- 2019-06-21 EP EP19822662.3A patent/EP3810202A4/en not_active Withdrawn
- 2019-06-21 CN CN201980041247.9A patent/CN112292152A/zh active Pending
- 2019-06-21 WO PCT/CN2019/092173 patent/WO2019242706A1/en active Application Filing
- 2019-06-21 US US17/254,685 patent/US20210268123A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN112292152A (zh) | 2021-01-29 |
US20210268123A1 (en) | 2021-09-02 |
EP3810202A1 (en) | 2021-04-28 |
EP3810202A4 (en) | 2022-04-20 |
WO2019242706A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202102696B (en) | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof | |
MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
CL2020003174S1 (es) | Dispositivo para administración de dosis. | |
PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
PH12020551934A1 (en) | Magl inhibitors | |
PH12019501076A1 (en) | Pharmaceutical formulations | |
PH12019500061A1 (en) | Oral gastroretentive formulations and uses thereof | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
PH12019502548A1 (en) | Pyrazole magl inhibitors | |
MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
CO2017001712A2 (es) | Formulaciones de compuestos biológicos para instilación | |
MX2021005038A (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas. | |
CL2019002808A1 (es) | Métodos para prevenir o tratar enfermedades oftálmicas. | |
HK1257466A2 (zh) | 皮膚病的藥物製劑 | |
MX2020007627A (es) | Uso de la carrimicina o de sus ingredientes activos. | |
IN2013MU03370A (zh) | ||
MX2020010938A (es) | Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo. | |
HK1257783A2 (zh) | 皮膚病的藥物製劑 | |
PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
MX2020006886A (es) | Sistema para suministro de medicamento. | |
CL2016003271A1 (es) | Métodos para tratar infecciones | |
MX2021012146A (es) | Formulacion de tableta vaginal. | |
ZA202105718B (en) | Novel composition |